Mild dyslipidemia accelerates tumorigenesis through expansion of Ly6C
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
14 09 2022
14 09 2022
Historique:
received:
02
10
2020
accepted:
24
08
2022
entrez:
14
9
2022
pubmed:
15
9
2022
medline:
17
9
2022
Statut:
epublish
Résumé
Cancer and cardiovascular disease (CVD) share common risk factors such as dyslipidemia, obesity and inflammation. However, the role of pro-atherogenic environment and its associated low-grade inflammation in tumor progression remains underexplored. Here we show that feeding C57BL/6J mice with a non-obesogenic high fat high cholesterol diet (HFHCD) for two weeks to induce mild dyslipidemia, increases the pool of circulating Ly6C
Identifiants
pubmed: 36104342
doi: 10.1038/s41467-022-33034-0
pii: 10.1038/s41467-022-33034-0
pmc: PMC9475043
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5399Subventions
Organisme : British Heart Foundation
ID : CH/10/001/27642
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
Mol Immunol. 2020 Jan;117:139-146
pubmed: 31778913
J Immunol. 2018 Jan 15;200(2):422-431
pubmed: 29311384
Cancer Cell. 2004 Dec;6(6):553-63
pubmed: 15607960
Eur Heart J. 2019 Dec 21;40(48):3901-3909
pubmed: 31504409
Annu Rev Pathol. 2016 May 23;11:421-49
pubmed: 27193454
Cell Rep. 2016 Apr 12;15(2):336-48
pubmed: 27050512
Nat Rev Immunol. 2015 Feb;15(2):104-16
pubmed: 25614320
Trends Immunol. 2016 Mar;37(3):208-220
pubmed: 26858199
Nat Med. 2020 Sep;26(9):1452-1458
pubmed: 32661390
J Exp Med. 2015 Feb 9;212(2):139-48
pubmed: 25601652
Lancet. 2017 Oct 21;390(10105):1833-1842
pubmed: 28855077
Blood. 2010 Nov 11;116(19):3955-63
pubmed: 20682855
Front Immunol. 2018 Nov 13;9:2629
pubmed: 30483271
J Lipid Res. 1964 Oct;5:600-8
pubmed: 14221106
Oncotarget. 2016 Jun 21;7(25):38959-38972
pubmed: 27029038
J Clin Invest. 2017 Aug 1;127(8):3039-3051
pubmed: 28691930
Int J Mol Sci. 2018 Jul 24;19(8):
pubmed: 30042333
Innovation (Camb). 2021 Jul 01;2(3):100141
pubmed: 34557778
Arch Intern Med. 2008 Aug 11;168(15):1617-24
pubmed: 18695075
Circulation. 2008 Apr 1;117(13):1649-57
pubmed: 18347211
Cancer Res. 2021 Mar 1;81(5):1201-1208
pubmed: 33203697
Circulation. 2016 Mar 15;133(11):1104-14
pubmed: 26976915
Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):378-88
pubmed: 25524776
Horm Metab Res. 2015 Oct;47(11):839-45
pubmed: 26340705
Biomed Pharmacother. 2002 Oct;56(8):365-79
pubmed: 12442909
J Clin Invest. 2007 Jan;117(1):195-205
pubmed: 17200719
Oncogene. 2013 Feb 21;32(8):961-7
pubmed: 22469977
Nat Med. 2018 Feb;24(2):144-153
pubmed: 29309059
J Immunol. 2007 Feb 1;178(3):1505-11
pubmed: 17237399
PLoS One. 2017 Jun 15;12(6):e0179065
pubmed: 28617818
Nat Commun. 2016 Aug 19;7:12528
pubmed: 27538380
Eur J Immunol. 2016 Apr;46(4):912-8
pubmed: 26692072
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):
pubmed: 33649199
Br J Cancer. 2020 Jan;122(1):4-22
pubmed: 31819192
Science. 2013 Nov 29;342(6162):1094-8
pubmed: 24288332
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
FASEB J. 2015 Mar;29(3):748-58
pubmed: 25411437
Nature. 2012 Jul 19;487(7407):325-9
pubmed: 22763456
Int J Cancer. 2015 May 15;136(10):2352-60
pubmed: 25353097
J Leukoc Biol. 2012 Jan;91(1):167-81
pubmed: 21954284
Nat Commun. 2018 Apr 3;9(1):1310
pubmed: 29615667
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
Nutr Cancer. 2007;59(2):207-16
pubmed: 18001216
Am J Cancer Res. 2019 Feb 01;9(2):219-227
pubmed: 30906624
Cold Spring Harb Perspect Biol. 2011 Mar 01;3(3):
pubmed: 21123394
J Am Coll Cardiol. 2017 Oct 31;70(18):2278-2289
pubmed: 29073957
Cell. 2018 Jan 11;172(1-2):147-161.e12
pubmed: 29328910
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2645-50
pubmed: 12598651
Hum Vaccin Immunother. 2022 May 31;18(3):1926759
pubmed: 34190675
Am J Pathol. 2010 Dec;177(6):3180-91
pubmed: 21088217
Cells. 2021 Dec 22;11(1):
pubmed: 35011579